Browse by Audience
Skip to content
Papers of the Week
Recombinant Herpes Zoster Vaccine (RZV) after Heart Transplantation: A Single Center Experience.
Authors
Abstract
Herpes zoster (HZ) results from reactivation of latent varicella zoster virus (VZV) presenting as a dermatomal rash. Diminished cellular immunity to VZV increases HZ risk and incidence in solid organ transplant (SOT) is higher than the general population. Immunogenicity and safety of the inactivated varicella vaccine (RZV, Shingrix) has been demonstrated in renal transplant (KT) but data in heart transplant (HT) are lacking.